Volume 8, Issue 4, July 2020, Page: 177-181
Neurocognitive Disorders in People Living with Human Immunodeficiency Virus Aged 50 Years Old and More in Yalgado Ouédraogo Teaching Hospital
Guira Oumar, Training and Research Unity in Health Sciences, University Joseph Ki Zerbo, Ouagadougou, Burkina Faso; Internal Medicine Department, Yalgado Ouédraogo Teaching Hospital, Ouagadougou, Burkina Faso
Zombre Yacine, Internal Medicine Department, Yalgado Ouédraogo Teaching Hospital, Ouagadougou, Burkina Faso
Tieno Herve, Training and Research Unity in Health Sciences, University Joseph Ki Zerbo, Ouagadougou, Burkina Faso; Internal Medicine Department, Bogodogo Teaching Hospital, Ouagadougou, BurkinaFaso
Drabo Youssouf Joseph, Training and Research Unity in Health Sciences, University Joseph Ki Zerbo, Ouagadougou, Burkina Faso; Internal Medicine Department, Yalgado Ouédraogo Teaching Hospital, Ouagadougou, Burkina Faso
Received: Jun. 8, 2020;       Accepted: Jul. 7, 2020;       Published: Jul. 23, 2020
DOI: 10.11648/j.ajim.20200804.16      View  21      Downloads  26
Abstract
A screening of neurocognitive disorders is required in people living with HIV (PLHIV) to improve their care. We aimed to determine their prevalence, their clinical features and identify their associated factors and their nosology in PLHIV aged 50 years old and more. This cross- sectional study from prospective data was carried out in Yalgado Ouédraogo Teaching Hospital, from February to April, 2019. PLHIV aged 50 years old and more were concerned. Those on antiretroviral therapy for at least 6 months were included. Those having a mental dysfunction that did not allow the use of the questionnaire were not included. Baseline data, those relating to HIV, cognitive and daily living capacities assessment, and the nosology of neurocognitive disorders were collected. Daily living capacities were assessed by the Instrumental Activities of Daily Living score, and the cognitive functions by the Mini Mental State Examination. The Chi-square’s or the Fisher’s test and the Student’s test were used to compare respectively the proportions and the means. The factors for which the p-value was less than 0.20 in a bivariate analysis were included into a logistic regression model for a multivariate analysis with a significance of p set at < 0.05. One hundred and two patients were studied: 46 males (45.1%), 56 females (54.9%). The mean age was 57±5.6 years. The main antecedent was alcohol consumption (34.3%). Fifty-nine patients had a nadir of CD4 below 200 cel/µl. Eighty one HIV1 patients had an undetectable updated viral load. The mean duration since HIV diagnosis was 147±62.0 and that of antiretroviral therapy 130±50.0 months. Twenty four (23.5%) patients had neurocognitive disorders, particularly in the fields of attention (100%) and memory (87.5%). A simultaneous disorder in attention, memory and language was the common phenotype (33.3%). It was Asymptomatic Neurocognitive Impairment (66.6%), Minor Neurocognitive Disorders (33.3%). The nosological groups were: “Possible HIV Associated Neurocognitive Disorders (HAND)” (95.83%), “Probable HAND” (4.17%), “Certain HAND” and Secondary neurocognitive disorders (0%). In a bivariate analysis, age ≥ 65, male gender, socio-cultural status 3 (NSC3), opportunistic infection, the nadir of CD4 were the factors with a p-value ≤ 0.20. In a multivariate analysis, age (OR=4.55) and NSC3 (OR=2.55) were associated with neurocognitive disorders with respective p-values 0.03 and 0.04. Neurocognitive disorders are not rare in PLHIV aged 50 years old and more in Burkina Faso. However, appropriate assessment tools have to be developed in accordance with the population’s socio-cultural specifities.
Keywords
Neurocognitive Disorders, HIV, Sub-Saharan Africa
To cite this article
Guira Oumar, Zombre Yacine, Tieno Herve, Drabo Youssouf Joseph, Neurocognitive Disorders in People Living with Human Immunodeficiency Virus Aged 50 Years Old and More in Yalgado Ouédraogo Teaching Hospital, American Journal of Internal Medicine. Vol. 8, No. 4, 2020, pp. 177-181. doi: 10.11648/j.ajim.20200804.16
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
https://www.has-sante.fr. Haute Autorité de Santé. Parcours de soins des patients présentant un trouble neurocognitif associé à la maladie d’Alzheimer ou à une maladie apparentée.
[2]
Smail R. C, Brew B. J. HIV-associated Neurocognitive Disorder. Handb Clin Neurol 2018; 152: 75-97.
[3]
Mc Arthur JC, Steiner J, Sachtor Netal. Human immune deficiency virus-associated neurocognitive disorder: Mind the gap. Ann Neurol 2010; 67 (6): 699-714.
[4]
Moulinier A. Manifestations neurologiques. In Girard P-M, Katlama C, Pialoux G. VIH. Paris: doin; 2011: p 126-130.
[5]
https://www.has-sante.fr. Haute Autorité de Santé. VIH. Consultation de suivi en médicine générale des personnes sous traitement antirétroviral.
[6]
Sacktor N. Changing Clinical Phenotypes of HIV-Associated Neurocognitive Disorders. J Neurovirol 2018; 24 (2): 141-145.
[7]
Eggers C, Arendt G, Hahn K, Husstedt I. W, Maschke M, Neuen-Jacob E, and al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol 2017; 264: 1715-1727.
[8]
Bonnet F, Amieva H, Marquant F et al. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS 2013; 27: 391-400.
[9]
Geny C. Troubles cognitifs et infection par le virus de l’immunodéficience humaine. Lettre de l’infectiologue 2012; XXVII (5): 198-204.
[10]
Mugendi A. G, Kubo M. N, Nyamu D. G, Mwaniki L. M, Wahome S. K, Haberer J. E. Prevalence and Correlates of Neurocognitive Disorders among HIV Patients on Antiretroviral Therapy at a Kenyan Hospital. Neurology Research International 2019; 1-10.
[11]
Kalafat M, Hugonot Diener L, Poitrenaud J. Standardisation et étalonnage français du Mini Mental State, version GRECO. Revue de Neuropsychologie 2003; 13 (2): 209-236.
[12]
Mwangala P. N, Newton C. R, Abas M, Abubakar A. Screening tools for HIV-associated neurocognitive disorders among adults living with HIV in sub-Saharan Africa: A scoping review. AAS Open Research 2019, 1: 28: 1-22
[13]
Lescure F X, Moulignier A. Troubles cognitifs associés à l’infection VIH. Journal des Anti-infectieux 2014; 16 (2): 64-73.
[14]
Vivithanaporn P, Heo G, Gamble Jetal. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology2010; 75: 1150-8.
[15]
Namagga J. K. Prevalence and Risk Factors of HIV-Associated Neurocognitive Disorders in Rural Southwestern Uganda. J Assoc Nurses AIDS Care 2019; 30 (5): 531-538.
[16]
Nyamayaro P, Gouse H, Hakim J, Robbins R. N, Chibanda D. Neurocognitive impairment in treatment experienced adults living with HIV attending primary care clinics in Zimbabwe. BMC Infectious Diseases 2020; 20: 383: 1-20.
[17]
Yusuf J, Hassan A, Mamman A. I, Muktar H. M, Suleiman A. M, Baiyewu O. Prevalence of HIV-associated neurocognitive disorder (HAND) among patients attending a tertiary health facility in northern Nigeria. Journal of the International Association of Providers of AIDS Care (JIAPAC) 2017; 16 (1): 48-55.
[18]
Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011; 19: 137-42.
[19]
Barukh K. Dépistage et prise en charge des troubles cognitifs liés au VIH : évaluation de la filière EVACOG. Thèse de doctorat en médecine, université Paris Diderot-Paris7; 2014. P 71.
[20]
Moulignier A. Le complexe démentiel associé au VIH : aspects particuliers chez les sujets âgés. Psychol Neuropsychiatr vieil 2007; 5 (3): 193-207.
[21]
www.anrs.fr. Méda N, Tuaillon E, Kania Detal. Hepatitis B and C seroprevalence, Burkina Faso: across-sectional study.
Browse journals by subject